Annie Fang

585 total citations
29 papers, 394 citations indexed

About

Annie Fang is a scholar working on Infectious Diseases, Epidemiology and Virology. According to data from OpenAlex, Annie Fang has authored 29 papers receiving a total of 394 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Infectious Diseases, 10 papers in Epidemiology and 7 papers in Virology. Recurrent topics in Annie Fang's work include HIV/AIDS drug development and treatment (8 papers), HIV Research and Treatment (7 papers) and HIV/AIDS Research and Interventions (6 papers). Annie Fang is often cited by papers focused on HIV/AIDS drug development and treatment (8 papers), HIV Research and Treatment (7 papers) and HIV/AIDS Research and Interventions (6 papers). Annie Fang collaborates with scholars based in United States, France and United Kingdom. Annie Fang's co-authors include Bharat Damle, Paul Glue, Robert R. LaBadie, Sonia P. Sanchez, Jayvant Heera, Manoli Vourvahis, Srinivas Rao Valluri, Christopher L. Shaffer, Renato J. Scialis and Mithat Gunduz and has published in prestigious journals such as Blood, Antimicrobial Agents and Chemotherapy and AIDS.

In The Last Decade

Annie Fang

29 papers receiving 383 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Annie Fang United States	13	155	117	64	63	59	29	394
Marie‐Charlotte Hallouin France	10	148 1.0×	92 0.8×	46 0.7×	113 1.8×	45 0.8×	13	563
Dean Follman United States	6	110 0.7×	123 1.1×	45 0.7×	52 0.8×	39 0.7×	7	712
William M. O’Neil Canada	12	41 0.3×	126 1.1×	49 0.8×	52 0.8×	77 1.3×	16	432
Tyler S. Finn United States	9	133 0.9×	49 0.4×	132 2.1×	155 2.5×	60 1.0×	10	595
M. Levacher France	12	243 1.6×	159 1.4×	50 0.8×	32 0.5×	68 1.2×	25	655
Munjal Patel United States	7	60 0.4×	87 0.7×	125 2.0×	37 0.6×	45 0.8×	21	439
Juergen Loeffler Germany	14	147 0.9×	389 3.3×	50 0.8×	94 1.5×	55 0.9×	22	561
Debra Ogata-Arakaki United States	10	214 1.4×	240 2.1×	31 0.5×	28 0.4×	32 0.5×	13	437
Daolun Zhang France	9	113 0.7×	99 0.8×	169 2.6×	56 0.9×	42 0.7×	12	445
Joan Antoni Schoenenberger-Arnaiz Spain	13	35 0.2×	146 1.2×	45 0.7×	70 1.1×	141 2.4×	33	485

Countries citing papers authored by Annie Fang

Since Specialization

Citations

This map shows the geographic impact of Annie Fang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annie Fang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annie Fang more than expected).

Fields of papers citing papers by Annie Fang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annie Fang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annie Fang. The network helps show where Annie Fang may publish in the future.

Co-authorship network of co-authors of Annie Fang

This figure shows the co-authorship network connecting the top 25 collaborators of Annie Fang. A scholar is included among the top collaborators of Annie Fang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annie Fang. Annie Fang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Leavitt, Andrew D., Kaan Kavaklı, Laurent Frenzel, et al.. (2024). Efficacy and Safety of Giroctocogene Fitelparvovec in Adults with Moderately Severe to Severe Hemophilia Α: Primary Analysis Results from the Phase 3 ΑFFINE Gene Therapy Trial. Blood. 144(Supplement 1). 1053–1053. 2 indexed citations

Frenzel, Laurent, Kaan Kavaklı, Robert Klamroth, et al.. (2023). Characterizing a Cohort of Patients with Hemophilia B Treated with Fidanacogene Elaparvovec from the Phase 3 Benegene-2 Study Who Returned to Factor IX Prophylaxis. Blood. 142(Supplement 1). 2257–2257. 2 indexed citations

Harrington, Thomas J., Adam Giermasz, Nathan Visweshwar, et al.. (2023). Four-Year Follow-up of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia Α. Blood. 142(Supplement 1). 1054–1054. 3 indexed citations

Giermasz, Adam, Nathan Visweshwar, Thomas J. Harrington, et al.. (2022). Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia Α. Blood. 140(Supplement 1). 7776–7777. 5 indexed citations

Visweshwar, Nathan, Thomas J. Harrington, Andrew D. Leavitt, et al.. (2021). Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia a. Blood. 138(Supplement 1). 564–564. 16 indexed citations

Leavitt, Andrew D., Barbara A. Konkle, Kimo C. Stine, et al.. (2020). Updated Follow-up of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (SB-525) Gene Therapy in Adults with Severe Hemophilia a. Blood. 136(Supplement 1). 12–12. 21 indexed citations

Heera, Jayvant, Srinivas Rao Valluri, Charles Craig, et al.. (2019). First prospective comparison of genotypic versus phenotypic tropism assays in predicting virologic responses to maraviroc in a phase 3 study.. PubMed. 42(2). 101–107. 1 indexed citations

Stellbrink, Hans-Jürgen, Andrew Carr, Michael S. Saag, et al.. (2016). Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment. AIDS. 30(8). 1229–1238. 31 indexed citations

Heera, Jayvant, Srinivas Rao Valluri, Charles Craig, et al.. (2014). First prospective comparison of genotypic vs phenotypic tropism assays in predicting virologic responses to Maraviroc (MVC) in a phase 3 study: MODERN. Journal of the International AIDS Society. 17(4S3). 19519–19519. 5 indexed citations

10.

Vourvahis, Manoli, et al.. (2013). The Effects of Boceprevir and Telaprevir on the Pharmacokinetics of Maraviroc. JAIDS Journal of Acquired Immune Deficiency Syndromes. 65(5). 564–570. 17 indexed citations

11.

Vourvahis, Manoli, et al.. (2013). Pharmacokinetic Interaction between Maraviroc and Fosamprenavir-Ritonavir: an Open-Label, Fixed-Sequence Study in Healthy Subjects. Antimicrobial Agents and Chemotherapy. 57(12). 6158–6164. 4 indexed citations

12.

Fang, Annie, et al.. (2012). Safety and Pharmacokinetics of Nelfinavir During the Second and Third Trimesters of Pregnancy and Postpartum. HIV Clinical Trials. 13(1). 46–59. 6 indexed citations

13.

Brier, Michael E., et al.. (2010). Pharmacokinetics of Dexrazoxane in Subjects With Impaired Kidney Function. The Journal of Clinical Pharmacology. 51(5). 731–738. 5 indexed citations

14.

Fang, Annie, James N. Palmer, Alexander G. Chiu, et al.. (2009). Pharmacokinetics of azithromycin in plasma and sinus mucosal tissue following administration of extended-release or immediate-release formulations in adult patients with chronic rhinosinusitis. International Journal of Antimicrobial Agents. 34(1). 67–71. 14 indexed citations

15.

Crandon, Jared L., Mary Anné Banevicius, Annie Fang, et al.. (2009). Bronchopulmonary Disposition of Intravenous Voriconazole and Anidulafungin Given in Combination to Healthy Adults. Antimicrobial Agents and Chemotherapy. 53(12). 5102–5107. 43 indexed citations

16.

Andrews, Emma, et al.. (2008). Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co‐administered in healthy female subjects. British Journal of Clinical Pharmacology. 65(4). 531–539. 33 indexed citations

17.

Rautiainen, Markus, et al.. (2008). Pharmacokinetics of azithromycin in serum and sinus fluid after administration of extended-release and immediate-release formulations in patients with acute bacterial sinusitis. International Journal of Antimicrobial Agents. 31(6). 561–566. 16 indexed citations

18.

Fang, Annie, et al.. (2007). Significant Decrease in Nelfinavir Systemic Exposure After Omeprazole Coadministration in Healthy Subjects. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 28(1). 42–50. 28 indexed citations

19.

Shaffer, Christopher L., Mithat Gunduz, Renato J. Scialis, & Annie Fang. (2007). Metabolism and Disposition of a Selective α7 Nicotinic Acetylcholine Receptor Agonist in Humans. Drug Metabolism and Disposition. 35(7). 1188–1195. 22 indexed citations

20.

Glue, Paul, Annie Fang, Kuan Gandelman, & Brian Klee. (2006). Pharmacokinetics of an Extended Release Formulation of Alprazolam (Xanax XR) in Healthy Normal Adolescent and Adult Volunteers. American Journal of Therapeutics. 13(5). 418–422. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact